Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Clopidogrel-Paclitaxel Drug-Drug Interaction: A Pharmacoepidemiologic Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Comment on: "Cell Therapy for Heart Disease: Trial Sequential Analyses of Two Cochrane Reviews"

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The mitochondria in heart failure: a target for coenzyme Q10 therapy?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Antipsychotics and associated risk of out-of-hospital cardiac arrest

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Enhanced detection of circulating tumor DNA by fragment size analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Patient information in phase I trials: A systematic review

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Paclitaxel is mainly eliminated by CYP2C8 in the liver. CYP2C8 is strongly inhibited by the clopidogrel metabolite acyl-β-D-glucuronide. To determine if this interaction has clinical relevance, we identified 48 patients treated with clopidogrel and paclitaxel using databases and a prescription register. Peripheral sensory neuropathy was retrospectively evaluated from medical charts and compared to that of 88 age- and sex-matched controls treated with paclitaxel and low-dose aspirin. By a cumulative dose of 1,500 mg paclitaxel, 35% of the patients had developed severe neuropathy. The overall hazard ratio between clopidogrel use and severe paclitaxel neuropathy was 1.7 (95% confidence interval, 0.9-3.0). Among those receiving a high-dose paclitaxel regimen, the hazard ratio was 2.3 (95% confidence interval, 1.1-4.5). Our study indicates that clopidogrel is associated with a clinically relevant increased risk of neuropathy in patients treated with high-dose paclitaxel.

OriginalsprogEngelsk
TidsskriftClinical Pharmacology and Therapeutics
Vol/bind102
Udgave nummer3
Sider (fra-til)547-553
Antal sider7
ISSN0009-9236
DOI
StatusUdgivet - sep. 2017

ID: 52073264